NCT03860272 2025-02-06Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled
NCT04607200 2022-01-11AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaAgenus Inc.Phase 2 Withdrawn